reports
- Jamila El Bougrini
- Thibaut Voglimacci-Stephanopoli
- Jamila El Bougrini
- Thibaut Voglimacci-Stephanopoli
- Jamila El Bougrini
- Thibaut Voglimacci-Stephanopoli
- Jamila El Bougrini
- Thibaut Voglimacci-Stephanopoli
- Jamila El Bougrini
- Thibaut Voglimacci-Stephanopoli
- Jamila El Bougrini
- Thibaut Voglimacci-Stephanopoli
- Jamila El Bougrini
- Thibaut Voglimacci-Stephanopoli
QIA QIAGEN NV
A1XEH4 CROSSJECT SA
TNG TRANSGENE SA
A1XAEB QUANTUM GENOMICS
VLS VALNEVA SE
ALCAR CARMAT SA
GRF GRIFOLS S.A. CLASS A
ALINS INTRASENSE SA
ORY ORYZON GENOMICS
DIA DIASORIN S.P.A.
ADOC ADOCIA SA
ALVAL VALBIOTIS SA
BIM BIOMERIEUX SA
AFFLUENT MEDICAL SAS
ALMDP MEDESIS PHARMA SA
ALNFL NFL BIOSCIENCES SAS
ALTME TME PHARMA N.V.
ALVIN VINPAI
- Jamila El Bougrini
- Thibaut Voglimacci-Stephanopoli
QIA QIAGEN NV
A1XEH4 CROSSJECT SA
TNG TRANSGENE SA
A1XAEB QUANTUM GENOMICS
VLS VALNEVA SE
ALCAR CARMAT SA
GRF GRIFOLS S.A. CLASS A
ALINS INTRASENSE SA
ORY ORYZON GENOMICS
DIA DIASORIN S.P.A.
ADOC ADOCIA SA
ALVAL VALBIOTIS SA
BIM BIOMERIEUX SA
AFFLUENT MEDICAL SAS
ALMDP MEDESIS PHARMA SA
ALNFL NFL BIOSCIENCES SAS
ALTME TME PHARMA N.V.
ALVIN VINPAI
- Jamila El Bougrini
- Thibaut Voglimacci-Stephanopoli
- Jamila El Bougrini
- Thibaut Voglimacci-Stephanopoli
- Jamila El Bougrini
- Thibaut Voglimacci-Stephanopoli
Diasorin S.P.A: 1 director
A director at Diasorin S.P.A bought 1,500 shares at 97.642EUR and the significance rating of the trade was 65/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...
- Jamila El Bougrini
- Thibaut Voglimacci-Stephanopoli
- Jamila El Bougrini
- Thibaut Voglimacci-Stephanopoli
- Jamila El Bougrini
- Thibaut Voglimacci-Stephanopoli
- Jamila El Bougrini
- Thibaut Voglimacci-Stephanopoli
- Jamila El Bougrini
- Thibaut Voglimacci-Stephanopoli
Increased risk weighs on DIASORIN, penalising its rating down to Neut...
The independent financial analyst theScreener just lowered the general evaluation of DIASORIN (IT), active in the Biotechnology industry. As regards its fundamental valuation, the title still shows 1 out of 4 possible stars. Its market behaviour, however, has slightly deteriorated and will be qualified as moderately risky moving forward. theScreener considers that these new qualifications justify an overall rating downgrade to Neutral. As of the analysis date January 25, 2022, the closing price ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.